Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Share-based Compensation (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Share-based Compensation for 16 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 20.53% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.8 million, a 19.15% increase, with the full-year FY2025 number at $7.8 million, up 19.15% from a year prior.
  • Share-based Compensation was $2.1 million for Q4 2025 at Lemaitre Vascular, up from $1.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.1 million in Q4 2025 to a low of $684000.0 in Q4 2022.
  • A 5-year average of $1.4 million and a median of $1.3 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: fell 22.8% in 2022, then soared 105.26% in 2023.
  • Lemaitre Vascular's Share-based Compensation stood at $886000.0 in 2021, then fell by 22.8% to $684000.0 in 2022, then skyrocketed by 105.26% to $1.4 million in 2023, then grew by 23.86% to $1.7 million in 2024, then grew by 20.53% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Share-based Compensation are $2.1 million (Q4 2025), $1.7 million (Q3 2025), and $1.9 million (Q2 2025).